Literature DB >> 20801767

Bringing forward reperfusion with oxygenated blood perfusion beyond arterial occlusion during endovascular procedures in patients with acute ischemic stroke.

M Ribo1, M Rubiera, J Pagola, D Rodriguez-Luna, P Meler, A Flores, J Alvarez-Sabin, C A Molina.   

Abstract

BACKGROUND AND
PURPOSE: High recanalization rates achieved with endovascular procedures are not always followed by the expected clinical improvement. These time-consuming procedures imply a delayed reperfusion despite the capacity of earlier intravascular microcatheter bypass to the ischemic tissue beyond the clot. We aimed to explore the safety and feasibility of MOB beyond the clot.
MATERIALS AND METHODS: We studied patients with stroke undergoing endovascular procedures. The timing of procedural steps was recorded. We then explored the safety and feasibility of repeated femoral artery MOB injections beyond the occlusion every time the clot was crossed in 17 patients. Pre- and postocclusion flow was continuously monitored with TCD.
RESULTS: We studied 60 patients (mean age, 70 ± 11 years; median NIHSS score, 20; IR, 18-21). Of them, 33 (55%) received IV-tPA before the endovascular procedure. The following arteries were occluded: the MCA (63.3%, n = 38) and the ICA (36.6%, n = 22). The TSO to arterial puncture was 193 ± 77 minutes. The occluding clot was successfully crossed with the microcatheter in 46 patients (76.6%; mean TSO, 228 ± 82 minutes). Recanalization was achieved in 44 patients (73.2%; mean TSO, 328 ± 144 minutes). Repeated MOB injections were performed in 17 patients. Patients with/without MOB presented with similar baseline characteristics. The median number of MOB injections was 2 (IR, 2-3), and the median injected blood volume was 40 mL (IR, 27.5-50). The mean time from first MOB to arterial recanalization was 136 ± 86 minutes. During MOB, a nonpulsatile flow appeared in previously nonvisible distal branches on TCD.
CONCLUSIONS: In this small series, oxygenated blood delivered through a microcatheter positioned distal to the site of occlusion was feasible and safe. Until final recanalization is achieved, MOB injections may generate intermittent reperfusion for up to 2 hours.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801767      PMCID: PMC7964000          DOI: 10.3174/ajnr.A2221

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  17 in total

1.  The Interventional Management of Stroke (IMS) II Study.

Authors: 
Journal:  Stroke       Date:  2007-05-24       Impact factor: 7.914

2.  Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes.

Authors:  T G Brott; E C Haley; D E Levy; W Barsan; J Broderick; G L Sheppard; J Spilker; G L Kongable; S Massey; R Reed
Journal:  Stroke       Date:  1992-05       Impact factor: 7.914

3.  Time is brain--quantified.

Authors:  Jeffrey L Saver
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

4.  Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke.

Authors:  C A Molina; J Montaner; S Abilleira; B Ibarra; F Romero; J F Arenillas; J Alvarez-Sabín
Journal:  Stroke       Date:  2001-05       Impact factor: 7.914

5.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Authors:  J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

6.  Diagnostic criteria and yield of real-time transcranial Doppler monitoring of intra-arterial reperfusion procedures.

Authors:  Marta Rubiera; Luis Cava; Georgios Tsivgoulis; Damon E Patterson; Limin Zhao; Yi Zhang; Aaron M Anderson; Alice Robinson; Mark R Harrigan; Edward Underwood; Joseph Horton; Andrei V Alexandrov
Journal:  Stroke       Date:  2010-02-18       Impact factor: 7.914

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. The Dutch TIA Study Group.

Authors: 
Journal:  Stroke       Date:  1988-04       Impact factor: 7.914

9.  Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial.

Authors:  Wade S Smith; Gene Sung; Jeffrey Saver; Ronald Budzik; Gary Duckwiler; David S Liebeskind; Helmi L Lutsep; Marilyn M Rymer; Randall T Higashida; Sidney Starkman; Y Pierre Gobin; Donald Frei; Thomas Grobelny; Frank Hellinger; Dan Huddle; Chelsea Kidwell; Walter Koroshetz; Michael Marks; Gary Nesbit; Isaac E Silverman
Journal:  Stroke       Date:  2008-02-28       Impact factor: 7.914

10.  Microcatheter contrast injections during intra-arterial thrombolysis may increase intracranial hemorrhage risk.

Authors:  Pooja Khatri; Joseph P Broderick; Jane C Khoury; Janice A Carrozzella; Thomas A Tomsick
Journal:  Stroke       Date:  2008-09-04       Impact factor: 7.914

View more
  2 in total

Review 1.  Intra-arterial delivery of cell therapies for stroke.

Authors:  Vivek Misra; Aditya Lal; Ramy El Khoury; Peng R Chen; Sean I Savitz
Journal:  Stem Cells Dev       Date:  2012-02-15       Impact factor: 3.272

2.  The role of citicoline in neuroprotection and neurorepair in ischemic stroke.

Authors:  José Alvarez-Sabín; Gustavo C Román
Journal:  Brain Sci       Date:  2013-09-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.